4.8 Article

Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α-Dependent Pathway in Multiple Myeloma

期刊

CANCER RESEARCH
卷 69, 期 12, 页码 5082-5090

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-4603

关键词

-

类别

资金

  1. Multiple Myeloma Research Foundation Senior Research Grant Award
  2. Dunkin' Donuts Rising Star Award
  3. NIH [1P50 CA 1 00707, RO-1 CA 50947, PO-1 78378, CA134660-01]
  4. LeBow Family Fund to Cure Myeloma

向作者/读者索取更多资源

Bone marrow angiogenesis is associated with multiple myeloma (MM) progression. Here, we report high constitutive hypoxia-inducible factor-1 alpha (Hif-1 alpha) expression in MM cells, which is associated with oncogenic c-Myc. A drug screen for anti-MM agents that decrease Hif-1 alpha and c-Myc levels identified a variety of compounds, including bortezomib, lenalidomide, enzastaurin, and adaphostin. Functionally, based on transient knockdowns and overexpression, our data delineate a c-Myc/Hif-1 alpha-dependent pathway mediating vascular endothelial growth factor production and secretion. The antiangiogenic activity of our tool compound, adaphostin, was subsequently shown in a zebrafish model and translated into a preclinical in vitro and in vivo model of MM in the bone marrow milieu. Our data, therefore, identify Hif-1 alpha as a novel molecular target in MM and add another facet to anti-MM drug activity. [Cancer Res 2009;69(12):5082-90]

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Andreas Stadlbauer, Chunyan Sun, Heng Mei, Martin Pecherstorfer, Latifa Bakiri, Erwin F. Wagner, Giovanni Tonon, Martin Sattler, Yu Hu, Pierfrancesco Tassone, Dirk Jaeger, Klaus Podar

Summary: This study demonstrates a significant correlation between JunB and angiogenic factors in MM, independent of hypoxia. JunB plays a dual role as a mediator of MM cell survival, proliferation, drug resistance, and also promotes angiogenesis in the BM microenvironment. These findings suggest targeting JunB as a potential strategy in MM therapy.

LEUKEMIA (2021)

Correction Oncology

JunB is a key regulator of multiple myeloma bone marrow angiogenesis (May, 10.1038/s41375-021-01271-9, 2021)

Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, Andreas Stadlbauer, Chunyan Sun, Heng Mei, Martin Pecherstorfer, Latifa Bakiri, Erwin F. Wagner, Giovanni Tonon, Martin Sattler, Yu Hu, Pierfrancesco Tassone, Dirk Jaeger, Klaus Podar

LEUKEMIA (2021)

Meeting Abstract Hematology

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity

Judith Lind, Sonia Vallet, Karoline Kollmann, Osman Aksoy, Vincent Sunder-Plassmann, Fengjuan Fan, Elisabeth Zwickl-Traxler, Dagmar Stoiber, Latifa Bakiri, Erwin F. Wagner, Martin Sattler, Martin Percherstorfer, Klaus Podar

Meeting Abstract Hematology

Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

Osman Aksoy, Judith Lind, Vincent Sunder-Plassmann, Martin Percherstorfer, Sonia Vallet, Klaus Podar

Review Oncology

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma

Samantha Pozzi, Alessia Bari, Martin Pecherstorfer, Sonia Vallet

Summary: RRMM patients face increased toxicity risks due to prolonged exposure to multiple drugs. Preserving quality of life is crucial, and supportive care plays a key role in managing disease- and treatment-related complications. Novel strategies, such as anabolic bone agents and ALK inhibitors, are being investigated alongside established supportive therapies like erythropoietin-stimulating agents and bisphosphonates.

CANCERS (2021)

Review Oncology

Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?

Oronza A. Botrugno, Giovanni Tonon

Summary: Genomic instability is a major factor in drug resistance in cancers, including multiple myeloma; Replicative stress plays a key role in fueling genomic instability; Multiple myeloma cells rely on the ATR protein to cope with DNA damage.

CANCERS (2022)

Review Oncology

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

Klaus Podar, Xavier Leleu

Summary: Collaborative translational studies have enhanced our knowledge of multiple myeloma pathophysiology over the past two decades, but it remains an incurable disease requiring ongoing research to improve patient outcomes. Exciting therapeutic progress, including new drug approvals and emerging treatments in 2020/2021, continues to advance in the field of multiple myeloma.

CANCERS (2021)

Article Oncology

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group

Michael Leisch, Michael Pfeilstoecker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Bernd Hartmann, Andreas Petzer, Martin Schreder, David Kiesl, Sonia Vallet, Alexander Egle, Thomas Melchardt, Gudrun Piringer, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Manuel Drost, Richard Greil, Lisa Pleyer

Summary: Azacitidine is the only drug proven to prolong overall survival and is recommended for patients with certain types of leukemia. Adverse events during treatment with azacitidine were analyzed, and it was found that hematologic adverse events occurred at a similar rate compared to clinical trials, but gastrointestinal toxicities were less commonly reported.

CANCERS (2022)

Review Pharmacology & Pharmacy

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

Vincent Sunder-Plassmann, Osman Aksoy, Judith Lind, Martin Pecherstorfer, Sonia Vallet, Klaus Podar

Summary: This article summarizes the recent advances in MM immunotherapies presented at the 2021 Annual Meeting of the American Society of Hematology and provides an outlook on ongoing research efforts aiming to improve efficacy and reduce toxicity.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Article Cell Biology

Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition

Piera Tocci, Celia Roman, Rosanna Sestito, Valeriana Di Castro, Andrea Sacconi, Ivan Molineris, Francesca Paolini, Mariantonia Carosi, Giovanni Tonon, Giovanni Blandino, Anna Bagnato

Summary: PARP inhibitors have changed the treatment paradigm of HG-SOC, but their efficacy is limited in patients with high TP53 mutation rates. The overexpression of the ET-1/ET1R axis in HG-SOC is associated with poor prognosis and inhibits the DNA damage response induced by PARP inhibitors. The ET-1R antagonist macitentan, in combination with olaparib, shows promising results in suppressing metastatic progression in HG-SOC patient-derived xenografts.

CELL DEATH & DISEASE (2023)

Article Oncology

Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study

Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer, Philipp Wohlfarth, Ulrich Jaeger, Josef Singer

Summary: Patients with B-cell malignancies show improved antibody production after the third vaccination against SARS-CoV-2. However, those under active treatment with anti-CD19 CAR T-cells or anti-CD20 monoclonal antibodies face greater difficulties in developing neutralizing antibodies. Future studies with larger cohorts are needed to further understand the effective vaccination scheme for high-risk hematological patients.

CANCERS (2023)

Article Hematology

Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT

Lisa Pleyer, Marc Vaisband, Manuel Drost, Michael Pfeilstoecker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Angelika Pichler, Bernd Hartmann, Andreas Petzer, Martin Schreder, Clemens A. Schmitt, Sonia Vallet, Thomas Melchardt, Armin Zebisch, Petra Pichler, Nadja Zaborsky, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Jan Hasenauer, Julian Larcher-Senn, Richard Greil

Summary: The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with incomplete count recovery (CRi), both of which require an invasive BM evaluation. A new response type termed peripheral blood complete remission (PB-CR) is defined and validated in this study, which can be determined from the differential blood count and clinical parameters without necessitating a BM assessment.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Urology & Nephrology

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy

David D'Andrea, Shahrokh F. Shariat, Francesco Soria, Andrea Mari, Laura S. Mertens, Ettore Di Trapani, Diego M. Carrion, Benjamin Pradere, Renate Pichler, Ronan Filippot, Guillaume Grisay, Francesco Del Giudice, Ekaterina Laukhtina, David Paulnsteiner, Wojciech Krajewski, Sonia Vallet, Martina Maggi, Ettore De Berardinis, Mario Alvarez-Maestro, Stephan Bronimann, Fabrizio Di Maida, Bas W. G. van Rhijn, Kees Hendricksen, Marco Moschini

Summary: Patients with primary MIBC have better pathologic response rates to NAC in comparison to patients with secondary MIBC. Chemoresistance might be related to the different genomic profile of primary versus secondary MIBC.

EUROPEAN UROLOGY OPEN SCIENCE (2022)

Article Oncology

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study

Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, David Niehaus, Inken Dralle-Filiz, Cord Matthies, Tamas Dienes, Stefanie Zschaebitz, Pia Paffenholz, Tanja Gschliesser, Renate Pichler, Michal Mego, Pia Bader, Friedemann Zengerling, Julia Heinzelbecker, Philipp Krausewitz, Susanne Krege, Gaetano Aurilio, Cem Aksoy, Marcus Hentrich, Christoph Seidel, Peter Toerzsoek, Tim Nestler, Matthaeus Majewski, Andreas Hiester, Tomas Buchler, Sonia Vallet, Hana Studentova, Sandra Schoenburg, Dora Niedersuess-Beke, Julia Ring, Emanuela Trenti, Axel Heidenreich, Christian Wuelfing, Hendrik Isbarn, Uwe Pichlmeier, Martin Pichler

Summary: The 1xBEP regimen is a safe treatment for patients with CS1 NSGCT, with a low relapse rate and a high cure rate for relapses.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Article Oncology

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

Josef Singer, Nguyen-Son Le, Daniel Mattes, Valerie Klamminger, Klaus Hackner, Nicole Kolinsky, Michaela Scherb, Peter Errhalt, Gudrun Kreye, Martin Pecherstorfer, Sonia Vallet, Klaus Podar

Summary: Vaccination is the primary public health strategy to combat the COVID-19 pandemic, with solid tumor and hematologic patients being at higher risk of severe complications. Data on immune responses to COVID-19 vaccines in these patients are scarce. Complete vaccination is a valuable predictor for high anti-SARS-CoV-2 antibody responses in these vulnerable patient groups.

CANCERS (2021)

暂无数据